LAG3 and cancer: Notably, immune checkpoint inhibitors (ICIs) including antiprogrammed cell death-1 (PD-1), antiprogrammed cell death ligand-1 (PD-L1), anticytotoxic T-lymphocyte antigen-4 (CTLA-4) and lymphocyte activation gene-3 (LAG-3) such as nivolumab, ipilimumab, and pembrolizumab have become integral components in the therapeutic arsenals for over 20 different cancer types [1,2,3].